GlassScriptPhysician profile
Esther Suh
NPI 1740993351
$1,690.35
in general payments reported to CMS, 2019-2025
11 companies · $25.87 in 2025
The $25.87 reported for 2025 was less than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $779 · 2024: $886 · 2025: $25.87.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,690.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,690.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $345.63 | 2023-2024 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $309.38 | 2023-2024 | Prolia, Evenity, Repatha |
| Glaxosmithkline, LLC. | $215.50 | 2023-2025 | Nucala |
| Bayer Healthcare Pharmaceuticals INC. | $184.19 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $131.17 | 2023-2024 | Tezspire, Fasenra, Farxiga |
| Otsuka America Pharmaceutical, INC. | $125.00 | 2024 | Rexulti |
| Intra-Sana Laboratories | $94.68 | 2024 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Novartis Pharmaceuticals Corporation | $92.61 | 2024 | |
| Esperion Therapeutics, INC. | $74.85 | 2023 | Nexletol, Nexlizet |
| Novo Nordisk INC | $67.23 | 2023-2024 | Ozempic, Rybelsus |
| Abbvie INC. | $50.11 | 2023-2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Esther Suh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.